Scynexis (SCYX) Misses Q1 Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Scynexis (SCYX) Misses Q1 Expectations
May 15, 2015 8:30 AM EDT
RESEARCH TRIANGLE PARK, N.C., May 15, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq: SCYX) today reported financial results for the first quarter of 2015.
"We are in a strong financial position following the successful completion of our follow-on public offering in April 2015, which resulted in net proceeds of $37.8 million," said Marco Taglietti, SCYNEXIS' Chief Executive Officer. "These cash resources are projected to allow us to progress our lead product candidate, SCY-078, through several key milestones, bringing us closer to providing a new treatment option to patients with life-threatening invasive fungal infections."
... More
May 14, 2015 8:30 AM EDT
RESEARCH TRIANGLE PARK, N.C., May 14, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the appointment of David Angulo, M.D., as Chief Medical Officer, effective June 1, 2015. Dr. Angulo will be responsible for advancing the company's clinical development strategy and clinical operations for SCY-078, SCYNEXIS' lead clinical asset, currently in Phase 2 clinical development for the treatment of invasive fungal infections.
"David brings a wealth of relevant experience to SCYNEXIS, both through his tenure as an infectious disease physician and through clinical and corporate roles where he... More
